Chugai Launches New Mid-term Plan With Investment Prospects; Eisai Battles For Its Growth Drivers – Japan Earnings Profiles
This article was originally published in PharmAsia News
Executive Summary
Japan’s earnings season highlights new global strategies for Japan’s leading pharmaceutical companies.
You may also be interested in...
Roche Upbeat On Recent Launches, Oncology And Actemra To Drive Growth Through Mid-Term
Roche presented a mixed sales picture across regions and products in a first quarter 2012 earnings call. Management highlighted a busy regulatory quarter with two new NME launches and five positive Phase III trials and filings, but also reported generic and competitive threats to key products.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.